Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
Open Access
- 1 September 2013
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 21 (9) , 1796-1805
- https://doi.org/10.1038/mt.2013.119
Abstract
No abstract availableThis publication has 51 references indexed in Scilit:
- Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural ProteinsGastroenterology, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- The Hepatitis C Virus Non-structural NS5A Protein Impairs Both the Innate and Adaptive Hepatic Immune Response in VivoJournal of Biological Chemistry, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccineVaccine, 2008
- DNA vaccines: ready for prime time?Nature Reviews Genetics, 2008
- High Level of PD-1 Expression on Hepatitis C Virus (HCV)-Specific CD8 + and CD4 + T Cells during Acute HCV Infection, Irrespective of Clinical OutcomeJournal of Virology, 2008
- DNA vaccines: precision tools for activating effective immunity against cancerNature Reviews Cancer, 2008
- Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus MacaquesJournal of Virology, 2007
- Evasion of intracellular host defence by hepatitis C virusNature, 2005